title: Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment.
abstract: Discovery of the over-expression of Her-2/neu or the amplification of its regulatory gene in stomach and esophageal cancer has resulted in targeted treatment directed at this protein. The fact itself and its consequences have been the topic of an abundance of studies and clinical trials. In the present report we review the current state of the art as regards diagnosis of the over-expression and amplification of Her-2/neu, its inhibition as a new therapeutic concept, treatment toxicity, and the development of resistance to Her-2/neu as a limiting factor in stomach and esophageal adenocarcinoma.
authors.affiliation: Department of Pathology, General Hospital - Medical University of Vienna, Austria.
authors.forename: Judith
authors.initials: J
authors.lastname: Maresch
authors.forename: Sebastian F
authors.initials: SF
authors.lastname: Schoppmann
authors.forename: Christiane M R
authors.initials: CM
authors.lastname: Thallinger
authors.forename: Christoph C
authors.initials: CC
authors.lastname: Zielinski
authors.forename: Michael
authors.initials: M
authors.lastname: Hejna
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D005784:Gene Amplification / Q000187:drug effects; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics*; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human